13.09.2019 - Mallinckrodt has agreed to sell its wholly owned subsidiary BioVectra to an affiliate of private equity group H.I.G. Capital for $250 million. The price includes a fixed sum of...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)